Información de BioMarin Pharmaceutical Inc, dividendo de BioMarin Pharmaceutical Inc, actividades de los accionistas y más

Más Datos de BioMarin Pharmaceutical Inc Compañía

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Información de BioMarin Pharmaceutical Inc



Símbolo de cotizaciónBMRN

Nombre de la empresaBioMarin Pharmaceutical Inc

Fecha de salida a bolsaJul 23, 1999

Director ejecutivoMr. Alexander Hardy

Número de empleados3040

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 23

Dirección770 Lindaro Street

CiudadSAN RAFAEL

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal94901

Teléfono14155066700

Sitio Webhttps://www.biomarin.com/

Símbolo de cotizaciónBMRN

Fecha de salida a bolsaJul 23, 1999

Director ejecutivoMr. Alexander Hardy

Ejecutivos de BioMarin Pharmaceutical Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+305.05%

Ms. Barbara W. Bodem

Independent Director

8.83K

+305.05%

Ms. Elizabeth Mckey Anderson

Independent Director

--

Mr. Timothy Walbert

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

Otro

84.92M

10.45%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

272.55M

33.53%

Europe

243.14M

29.91%

Rest of the world

142.74M

17.56%

Latin America

98.12M

12.07%

ALDURAZYME net product revenues marked by Sanofi

56.44M

6.94%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

Otro

84.92M

10.45%

Estadísticas de accionistas

Actualizado: sáb., 16 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.84%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.86%

Viking Global Investors LP

6.40%

Otro

58.30%

Accionistas

Proporción

The Vanguard Group, Inc.

9.84%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.86%

Viking Global Investors LP

6.40%

Otro

58.30%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

43.91%

Investment Advisor/Hedge Fund

40.30%

Hedge Fund

7.65%

Pension Fund

3.13%

Research Firm

1.58%

Sovereign Wealth Fund

1.23%

Bank and Trust

1.14%

Individual Investor

0.75%

Venture Capital

0.34%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

1304

191.42M

99.64%

-19.19M

2025Q2

1333

195.10M

101.61%

-16.01M

2025Q1

1355

191.53M

99.87%

-20.72M

2024Q4

1336

190.53M

99.88%

-17.50M

2024Q3

1308

188.26M

98.81%

-22.17M

2024Q2

1293

192.58M

101.18%

-14.21M

2024Q1

1278

194.24M

102.38%

-11.23M

2023Q4

1294

193.16M

102.42%

-3.22M

2023Q3

1275

188.66M

100.18%

-4.68M

2023Q2

1283

185.80M

98.76%

-8.08M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

18.91M

9.85%

-8.07K

-0.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

18.04M

9.39%

-79.52K

-0.44%

Jun 30, 2025

PRIMECAP Management Company

15.77M

8.21%

-2.00M

-11.26%

Jun 30, 2025

Dodge & Cox

15.11M

7.87%

+153.07K

+1.02%

Jun 30, 2025

Viking Global Investors LP

12.29M

6.4%

+1.49M

+13.78%

Jun 30, 2025

State Street Investment Management (US)

8.85M

4.61%

+384.66K

+4.55%

Jun 30, 2025

AQR Capital Management, LLC

5.58M

2.91%

+2.65M

+90.74%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.47M

1.81%

+43.19K

+1.26%

Jun 30, 2025

Millennium Management LLC

2.83M

1.48%

+2.16M

+319.74%

Jun 30, 2025

Rothschild & Co Asset Management Europe SCS

1.97M

1.03%

-20.00

-0.00%

Aug 31, 2025

ETFs relacionados



Actualizado: lun., 6 de oct

Nombre

Proporción

Invesco Biotechnology & Genome ETF

4.74%

Global X Genomics & Biotechnology ETF

3.43%

First Trust NYSE Arca Biotechnology Index Fund

3.25%

Goldman Sachs Future Health Care Equity ETF

2.85%

SPDR S&P Biotech ETF

2.37%

WealthTrust DBS Long Term Growth ETF

2.11%

Alger Russell Innovation ETF

1.9%

First Trust Health Care Alphadex Fund

1.82%

Pacer Lunt MidCap Multi-Factor Alternator ETF

1.71%

Virtus LifeSci Biotech Products ETF

1.69%

Invesco Biotechnology & Genome ETF

Proporción4.74%

Global X Genomics & Biotechnology ETF

Proporción3.43%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.25%

Goldman Sachs Future Health Care Equity ETF

Proporción2.85%

SPDR S&P Biotech ETF

Proporción2.37%

WealthTrust DBS Long Term Growth ETF

Proporción2.11%

Alger Russell Innovation ETF

Proporción1.9%

First Trust Health Care Alphadex Fund

Proporción1.82%

Pacer Lunt MidCap Multi-Factor Alternator ETF

Proporción1.71%

Virtus LifeSci Biotech Products ETF

Proporción1.69%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos